
Conclusion of Unmarketable Parcel Share Sale Facility

Melbourne, Australia; 7 April 2017: Mach7 Technologies Limited (**Mach7** or the **Company**) (ASX:**M7T**) is pleased to advise that the sale of Mach7 shares under the Company's unmarketable parcel share sale facility announced on 10 February 2017 (**Facility**) has been completed, at a sale price of \$0.28 per share.

A total of 1,370 shareholders collectively holding 308,608 Mach7 shares participated in the Facility.

Shareholders who participated in the Facility will receive the proceeds from the sale (\$0.28 per share sold) shortly by way of bank transfer or cheque.

Immediately prior to the conclusion of the Facility, the Company had 3,050 shareholders. Following the settlement of the share sales under the Facility, the Company now has 1,670 shareholders. As a result of the successful conclusion of the Facility, the Company's shareholder base has been reduced by almost half.

The substantial reduction in the number of shareholders in the Company will significantly reduce the Company's administrative costs associated with maintaining a large share register, including printing and mailing costs and share registry expenses.

- ENDS

Contacts:

Jenni Pilcher
CEO Australia, CFO
+61 3 9646 2222 (Australia)
jenni.pilcher@mach7t.com

Alyn Tai
Company Secretary
+61 3 9286 7500 (Australia)
alyn.tai@mach7t.com

About Mach7 Technologies:

Mach7 Technologies (ASX:M7T) develops innovative enterprise imaging IT solutions that create a clear and complete view of the patient to inform diagnosis, reduce care delivery delays and costs, and improve patient outcomes. Mach7's award-winning enterprise imaging platform provides a vendor neutral foundation for unstructured data consolidation and communication to power interoperability and enables healthcare enterprises to build their best-of-breed clinical ecosystems. Mach7's sophisticated workflow tools, advanced [clinical viewing](#) and optimised [vendor neutral archiving](#) solutions unlock silos of legacy systems empowering healthcare providers to own, access and share patient data without boundaries. Visit www.mach7t.com

Mach7's wholly-owned subsidiary, 3D Medical Pty Ltd, provides medical specific 3D printing and is an exclusive distributor of various synergistic technologies including holographic projection. 3D Medical's innovative products leverage data already captured by conventional imaging modalities and apply it in more meaningful ways to deliver improved economic and patient outcomes. Visit www.3dmedical.com.au